SLC5A2 and diabetic kidney disease: As DAPA is generally continuously used in the long-period treatment of DKD in clinical practice and SGLT2 inhibitors, especially DAPA, are often administrated for 10-12w or longer time rather than 6 days – 8 weeks or less time for the treatment of DKD in db/db mice (21, 28–30); future studies should explore whether DAPA as a novel therapy for DKD can regulate the gut flora and we assumed that the prolonged intervention of DAPA has further benefits.